Dr Reddy's Q2FY27 Results: Call time and key dates

What the company has announced

Dr. Reddy’s Laboratories said it will announce its financial results for the quarter and six months ended September 30, 2026, on Friday, October 23, 2026. The results are expected to be released after a board meeting, as per the company’s outlined schedule. The update matters for investors because it is the next formal disclosure covering the September quarter, a key period for operational and margin trends in a pharmaceutical business.

The company has also scheduled an earnings call on the same day to discuss the numbers and answer investor questions. According to the schedule shared, the earnings discussion will be hosted as a webinar. Participants will need to register in advance to access the live stream.

Earnings call timing: IST and ET

Dr. Reddy’s earnings call is scheduled for 19:30 pm IST on Friday, October 23, 2026. The company has also provided the corresponding time for international participants as 10:00 am ET. The call is intended to provide commentary from the management team on quarterly performance and the half-year trend.

For investors who track Indian pharma companies through ADR-linked flows and global investor participation, the dual-time-zone disclosure is operationally useful. It also signals that the company expects participation from outside India.

Where investors can access the event

The webinar will be hosted by the company, with access routed through the pre-registration link available on Dr. Reddy’s official website. The company said registration is mandatory for participants. This structure is increasingly common for earnings calls because it helps manage attendance and ensures orderly Q&A.

In addition to the live webcast, Dr. Reddy’s said related material will also be disseminated through stock exchange platforms. A press meet presentation is expected to be uploaded on the company website (www.drreddys.com) and distributed via exchange channels.

Post-call transparency: audio and transcript

Dr. Reddy’s said that after the earnings call concludes, both the audio recording and the written transcript will be made available on its corporate website. The company also indicated that these will be accessible through stock exchange channels.

For investors who cannot attend the live webinar, the availability of a recording and transcript is important because it allows detailed review of management commentary, including responses to investor queries.

Key dates at a glance

What to track going into Q2FY27

The Q2FY27 results will cover the period from July 1, 2026 to September 30, 2026, and the accompanying half-year numbers will cover April to September 2026. Alongside the P&L, investors typically focus on business updates that management shares during the call, because these can clarify what drove quarter-on-quarter movement and how the company is positioning itself.

The company stated that the call will allow stakeholders to hear directly from management regarding financial performance and strategic direction. While the detailed agenda was not provided in the text, the format indicates a standard earnings discussion with a Q&A component.

Recent reported numbers for context

Market data points cited alongside the event schedule indicate that Dr. Reddy’s reported revenue of ₹8,099 crore in the most recent reported quarter referenced in the text. The same dataset cited an EPS of 38.60.

The text also cited profit metrics: Profit Before Tax of ₹553.30 crore and Net Profit of ₹435.60 crore, along with quarter-on-quarter comparisons for those metrics. Separately, another reference in the text stated net profit of ₹444.30 crore for Q1 2026-27 with a year-on-year decline percentage. Since these figures appear across different data excerpts, investors typically reconcile them with the company’s official financial statements once published.

Dividend and other market references mentioned

The text also noted that the company declared a dividend of ₹8.00 per share on May 12, 2026, for the quarter ending March 2026, with a stated dividend yield of 0.67%.

In derivatives, the text included an options snapshot for DRREDDY contracts expiring October 27, 2026, showing last traded prices and daily changes for select call strikes. Such data points can reflect near-term positioning around event risk, but they do not by themselves explain direction.

Market impact: why this event matters

The announcement sets a clear timetable for information release and management interaction, which is often a near-term catalyst for price discovery. A scheduled earnings call, combined with the commitment to publish an audio recording and transcript, increases the availability of management commentary to all market participants.

The market context in the text also highlighted that there was “no quarterly earnings forecast data” for the stock in one dataset, while another excerpt referenced longer-term growth expectations for earnings and revenue. In practice, the official results and management commentary tend to carry more weight immediately after publication because they provide the updated baseline for future estimates.

Analysis: what the scheduled call adds beyond the numbers

Quarterly results provide the statutory view, but the call can clarify drivers that are not easily visible in a headline set of figures. Investors generally look for explanations of quarter-on-quarter movement, year-on-year comparisons, and how management interprets the operating environment.

The company’s plan to distribute a press meet presentation via the website and exchange platforms suggests it intends to provide a structured summary in addition to the financial statements. For investors, that helps in comparing management’s narrative with the reported financial outcomes.

Conclusion

Dr. Reddy’s Laboratories will release Q2FY27 and half-year results for the period ended September 30, 2026, on October 23, 2026, followed by an earnings call at 7:30 pm IST. Participation in the call requires pre-registration through the company website, and the audio recording and transcript will be published after the session. The next confirmed milestone for investors is the board-linked results release and the subsequent management Q&A on the same day.